As the global response to COVID-19 continues to move from a state of national lockdowns to the re-opening of societies, diagnostic assay developers are confronting two major challenges. Firstly, how to handle manufacturing volumes when level of demand is so uncertain. Secondly, where to invest in non-COVID diagnostics innovation and for which disease areas. Emmanuel Abate at Cytiva talks more about these two challenges.